Phase 3
N=340
Prophylactic Ivermectin in COVID-19 Contacts
COVID
Bottom Line
View on ClinicalTrials.gov: NCT04422561 ↗Enrolled (actual)
340
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcome: Primary: Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath) — 15; 59 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Ivermectin Tablets (Drug)
- Age
- Pediatric, Adult, Older Adult · 16+ yrs
- Sex
- All
- Sponsor
- Zagazig University
- Primary completion
- Jul 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath) |
15; 59 | — |
| SECONDARY Development of COVID |
— | — |
Summary
asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms & diagnosis of COVID -19
Eligibility Criteria
Inclusion Criteria
family contact of confirmed COVID-19 case
Exclusion Criteria
- refuse to participate and receive the drug pregnancy or lactation known hypersensitivity to ivermectin
Data sourced from ClinicalTrials.gov (NCT04422561). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.